Inhibition of cell death by ribosomal protein L35a

Cancer Lett. 2002 Jun 28;180(2):195-202. doi: 10.1016/s0304-3835(02)00024-1.

Abstract

In order to better understand how tumor cells develop resistance to chemotherapy drugs, we screened a human cDNA expression library in Jurkat cells for cDNA's that conferred resistance to doxorubicin-induced cell death. One of the cDNA's isolated in the screen codes for ribosomal protein L35a, a component of the large subunit of the ribosome. Jurkat cells engineered to overexpress L35a protein were more resistant not only to doxorubicin but also to UV-irradiation, anti-Fas antibody, and serum starvation compared to Jurkat cells expressing endogenous levels of L35a. Jurkat cells overexpressing L35a did not have increased levels of the anti-apoptotic proteins Bcl-2 or Bcl-xL, the drug efflux pump P-glycoprotein, nor altered cellular growth kinetics or total protein synthesis. Our results provide new insight into L35a function and suggest that it may have a role in the cellular response to cytotoxic damage. Since L35a RNA is overexpressed in a significant number of glioblastoma multiforme (GBM) brain tumors, our results may stimulate further investigation into the possible role of L35a in the resistance of GBM to cytotoxic therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Death
  • Cell Division
  • DNA, Complementary / isolation & purification
  • Drug Resistance, Neoplasm
  • Glioblastoma / drug therapy
  • Glioblastoma / metabolism
  • Humans
  • Jurkat Cells
  • Protein Biosynthesis
  • Ribosomal Proteins / genetics
  • Ribosomal Proteins / physiology*

Substances

  • DNA, Complementary
  • RPL35A protein, human
  • Ribosomal Proteins